Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809256 | 0.88 | IRAK4 (0.33) | MCL1RIPK1 | |
| SCHEMBL23809296 | 0.88 | GRM5 (0.47) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL23809465 | 0.86 | MTNR1A (0.37) | MCL1RIPK1NR4A2 | |
| SCHEMBL26581668 | 0.84 | MCL1 (0.39) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL23809246 | 0.84 | MEN1 (0.43) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL20605149 | 0.83 | HASPIN (0.38) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL23809218 | 0.83 | DRD2 (0.42) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL23809522 | 0.75 | MEN1 (0.47) | MEN1LMNAMAPTHTTKMT2A | |
| SCHEMBL20605164 | 0.74 | HSD11B1 (0.45) | — | |
| SCHEMBL26581741 | 0.74 | MCL1 (0.40) | MCL1DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | MEN1 3549/4885LMNA 3021/4885MAPT 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.